Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in obesity and related co-morbidities treatment. Alongside the acquisition, the two companies have announced a three-year research and development (R&D) collaboration to discover and develop new pharmaceutical solutions for obesity and […]
Danish pharma major Novo Nordisk A/S has confirmed its plan to acquire Montreal-based Inversago Pharma. The potential cash deal, reaching up to $1.075 billion, hinges on achieving specific development and commercial milestones. Inversago Pharma, a trailblazer in CB1 receptor-based treatments, focuses on addressing obesity, diabetes, and related metabolic disorders. Inversago Pharma’s INV-202: The Next Big […]
Novo Nordisk, a Danish pharmaceutical firm, has declared its intention to funnel DKK 15.9 billion ($2.3 billion) into expanding an existing Active Pharmaceutical Ingredient (API) production facility in Denmark. The expansion, starting in 2023, is set to bolster the future portfolio in the realm of serious chronic diseases. The colossal investment marks the 100-year anniversary […]
Rigel Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Rezlidhia (olutasidenib) capsules for relapsed or refractory (R/R) acute myeloid leukemia (AML) in adult patients. Rezlidhia is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as identified by an FDA-approved test. The oral, small molecule and mutant isocitrate […]
Novo Nordisk acquisition of Forma Therapeutics : Danish pharma company Novo Nordisk has closed the previously announced $1.1 billion acquisition of Forma Therapeutics, a clinical-stage biopharma company focused on developing drugs for the treatment of sickle cell disease (SCD) and rare blood disorders. As per the terms of the deal announced last month, shareholders of […]
HCL Technologies said that it has been roped in by Danish pharma company Novo Nordisk for providing global service desk and on-site support to the latter. As part of the partnership, the Indian firm will help Novo Nordisk in the transformation of its IT operations and develop world-class end-user experiences and propel efficiency across its […]
Novo Nordisk has signed a deal worth around $3.3 billion to acquire Dicerna Pharmaceuticals, a US-based biotech company focused on developing ribonucleic acid interference (RNAi) therapies. Based in Lexington, Massachusetts, Dicerna Pharmaceuticals leverages its proprietary GalXC and GalXC-Plus RNAi technologies to develop therapies to preferentially silence genes that either cause or contribute to disease. The […]
Novo Nordisk has been given approval from the US Food and Drug Administration (FDA) for an updated label for Saxenda (liraglutide) injection 3 mg for obesity treatment in adolescents in the 12–17 years age group. The approval is for adolescents who weigh more than 60 kg and have an initial body mass index (BMI) corresponding […]
Danish pharma company Novo Nordisk has agreed to acquire US drug delivery company Emisphere Technologies in a deal worth $1.8 billion. The proprietary drug delivery technologies of Emisphere Technologies include the Eligen SNAC technology and others which enable oral formulations of therapeutics. Since 2007, Novo Nordisk and the US company have collaborated. Eligen SNAC is […]
Novo Nordisk acquisition of Corvidia : Danish pharma company Novo Nordisk has agreed to acquire Corvidia Therapeutics from life sciences venture capital firm Sofinnova Partners in a deal worth up to $2.1 billion, in a move to expand its presence in cardiovascular disease. Corvidia Therapeutics, which is based in Boston, Massachusetts, was spun out from […]